EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8⁺ T Cells

The authors explored the combination between zeste homolog 2 (EZH2) inhibitor and an agonist antibody targeting the T cell costimulatory receptor 4-1BB.